AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)
Conditions
Diseases of the Cardiovascular System
Phase III
Volunteers
Health Professionals
What is the purpose of this trial?
Objectives
- Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
- Ages45 years and older
- GenderBoth
- Trial withUniversity of Cincinnati
- Start Date06/16/2020
- End Date01/18/2022
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Last Updated07/15/2021
- Study HIC#2000024124